ClinicalTrials.gg
CompletedNCT06686628Updated Apr 23, 2026

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

A Phase 1 interventional study of Amlitelimab and Midazolam in Dermatitis Atopic, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
11th of 11
23 · median 589
Started
2024
with 3 others
Phase 1
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
9 of 11
Sanofi

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2024, is the only one in phase 1, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab administration at Week 25).

The number of visits will be 23 or 21 visits for participants who decide to continue amlitelimab therapy in the long-term extension study LTS17367 (RIVER-AD) study.

03

Conditions studied

  • Dermatitis Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Male or female participant aged 18 to 65 years (inclusive), at the time of the is signed.
  • Participants must have AD as defined by the American Academy of Dermatology Consensus Criteria (2014) for 1 year or longer before signing of informed consent.
  • The EASI score ≥16 at Screening and Check-in (Day -1).
  • vIGA-AD score ≥3 (on the 0 to 4 vIGA-AD scale) at Screening and Check-in (Day -1).
  • AD involvement of ≥10% body surface area at Screening and Check-in (Day -1).
  • Participants must have documented history within 6 months prior to Screening and Check-in (Day -1), of either inadequate response (including inadequate efficacy or medical inadvisability) of topical treatments.
  • Body weight within 40 to 150 kg at Screening and Day 1 and (BMI) \<40 kg/m2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Known history of significant or suspected current significant immunosuppression, including history of invasive opportunistic, or helminthic infections.
  • Any or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and cured for more than 5 years prior to baseline).
  • Any concomitant illness that would, in the Investigator's opinion, inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure, and pulmonary disease.
  • Any medical condition which, in the Investigator's opinion may present an unreasonable risk to the study participants as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments.
  • Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline (1 week in the event of superficial skin infections) and any infection which as per Investigator's opinion precludes the participant's participation in the study or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals at Screening or Check--in (Day -1).
  • History or presence of substance abuse (including alcohol, nicotine) prior to Check-in (Day 1/V2) or regular alcohol consumption (>14 units per week for males and >7 units per week for females).
  • In the Investigator's opinion, medical conditions related to prior AD medications that have not healed/fully recovered for more than 2 weeks before the Screening visit, including, but not limited to, conjunctivitis, keratitis, eosinophilic conditions, arthralgia, herpes zoster, thrombosis.
  • Use of tobacco- or nicotine-containing products within 6 months prior to Check-in (Day -1).
  • Poor metabolizers for CYP2C9, CYP2C19, or CYP2D6 based on genotyping.
  • Treatment with a live (attenuated) vaccine within 12 weeks prior to baseline; failure to complete non-live immunization required by local regulation (eg, vaccination for COVID-19) at least 14 days prior to baseline.
  • Any to one or more of the following CYP cocktail study interventions, according to the applicable labeling:

    • Caffeine
    • Metoprolol
    • Midazolam
    • Omeprazole
    • Warfarin
  • Administration, within 14 days before baseline or within a period of 5 times the elimination half-life of the medication before baseline, whichever is longer, of any medication that is a known inducer or inhibitor of either one or more of the following CYP enzymes: , CYP2C19, CYP2C9, CYP2D6, and CYP1A2.
  • Administration, within 14 days before baseline or within a period of 5 times the elimination half-life of the medication before baseline, whichever is longer, of:

    • Caffeine
    • Metoprolol
    • Midazolam
    • Omeprazole
    • Warfarin.
  • Consumption of any 1 or more of the following food items and/or beverages within 1 week prior to baseline:

    • Grapefruit or grapefruit juice, apple or apple juice, orange or orange juice, lemons or lemon juice, limes or lime juice
    • Vegetables from the mustard green family (eg, broccoli)
    • Charbroiled meats
    • Caffeinated beverages, foods or drugs containing caffeine as well as decaffeinated coffee.

Participants who are not willing to abstain from the consumption of these food items and/or beverages for certain periods during the study (Day 1 to Day 8, and Day 168 to Day 183) will also be excluded.

  • History of excessive consumption of beverages containing caffeine (more than 4 cups or glasses per day). Participants who are not willing to abstain from the consumption of caffeine within 1 week prior to baseline, Day 1 to Day 8, and Day 168 to Day 183 will also be excluded.
  • Female participants who are using any form of hormonal (eg, oral, injectables, implants, patches, rings, hormone-impregnated IUDs) for birth control.
  • Have previously completed or withdrawn from this study or any other study investigating amlitelimab or have previously received a dose of an drug within the past 90 days or 5 half-lives, whichever is longer, prior to Check-in (Day -1).
  • Concurrent participation in any other clinical study, including non-interventional studies.
  • Participants positive for ; participants with any of the following results at Screening (Visit 1): presence of with or without HBV DNA PCR test or presence of antibody to hepatitis B core antigen (HBcAb) or presence of antibody to HBsAg with positive HBV DNA PCR test; positive total antibody confirmed by positive Hepatitis C virus RNA.
  • Known or suspected to any of the study interventions (amlitelimab, CYP substrates [cocktail compounds]) or , or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Amlitelimab and CYP substrates

    A single oral dose of a CYP450 substrates cocktail which will include caffeine, metoprolol, midazolam, omeprazole, and warfarin will be administered. A single dose of amlitelimab will then be administered on several days. A single oral dose of CYP450 substrates cocktail in combination with the last single dose of amlitelimab.

    Drug: Amlitelimab · Drug: Midazolam · Drug: Caffeine · Drug: Metoprolol · Drug: Omeprazole · Drug: Warfarin

Interventions

  • Pharmaceutical form: Injection solution Route of administration: SC injection

    Also known as: SAR445229

  • DrugMidazolam

    Pharmaceutical form: Solution Route of administration: Oral

  • DrugCaffeine

    Pharmaceutical form: Tablet Route of administration: Oral

  • Pharmaceutical form: Tablet Route of administration: Oral

  • DrugOmeprazole

    Pharmaceutical form: Capsule Route of administration: Oral

  • DrugWarfarin

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. AUC and AUClast for CYP substrates

    AUC = area under the serum/plasma concentration curve; AUClast = area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to the real time tlast.

    Time frame: Baseline (Day 1 to Day 8) and Day 176 to Day 183

Secondary outcomes

  1. Incidence of treatment-emergent adverse events, serious adverse events, adverse event of special interest, and potentially clinically significant abnormality.

    Time frame: Baseline through Day 316

  2. Serum amlitelimab concentrations (Ctrough) measured.

    Ctrough = plasma concentration pre-dose

    Time frame: Day 8 through Day 316

  3. Tmax, t1/2z, and tlast of CYP substrates alone and co-administered with amlitelimab

    tmax = time to reach the maximum plasma concentration observed t1/2z = terminal half-life associated with the terminal slope tlast= time corresponding to the last concentration above the limit of quantification

    Time frame: Baseline (Day 1 to Day 8) and Day 176 to Day 183

  4. Cmax of CYP substrates alone and co-administered with amlitelimab

    Cmax = maximum plasma concentration observed.

    Time frame: Baseline (Day 1 to Day 8) and Day 176 to Day 183

  5. Incidence of anti-drug antibodies of amlitelimab.

    Time frame: Baseline through Day 316

07

Study locations

1 site
  • Investigational Site Number : 2760001
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Nov 2025, 12 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 12 months is close to that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartActual
Nov 20, 2024
Primary completionActual
Nov 21, 2025
CompletionActual
Apr 2, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686628
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Nov 20, 2024
Primary completion
Nov 21, 2025
Completion
Apr 2, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion